What is Integrity Laboratories?
Integrity Laboratories is at the forefront of revolutionizing antimicrobial stewardship with its high-complexity clinical diagnostic solutions. The company's offerings, including the RespiPlex AIO test for infectious diseases and the intercept PCR molecular diagnostics platform, are engineered for rapid and precise results. By providing healthcare providers with actionable analytics and enabling targeted antimicrobial treatments, Integrity Laboratories significantly improves patient outcomes while concurrently driving down healthcare costs. Their strategic partnerships with established healthcare systems and insurance networks further solidify their market position.
How much funding has Integrity Laboratories raised?
Integrity Laboratories has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Integrity Laboratories
PPP
Public-Private Partnership
What's next for Integrity Laboratories?
With its recent strategic investment, Integrity Laboratories is poised for accelerated expansion and innovation in the competitive biotechnology landscape. The substantial capital will likely fuel further research and development into novel diagnostic technologies, enhance the scalability of their existing platforms, and broaden their market reach. This late-stage funding suggests a focus on solidifying market leadership, potentially through strategic acquisitions or deeper integration with healthcare provider networks. The company's trajectory indicates a strong commitment to advancing diagnostic precision and contributing to more effective, cost-efficient healthcare solutions.
See full Integrity Laboratories company page
